CÔNG TY CỔ PHẦN DƯỢC PHẨM TRUNG ƯƠNG 2
Digitally signed by CÔNG TY CỔ PHẦN DƯỢC PHẨM TRUNG ƯƠNG 2
DN: C=VN, S=HÀ NỘI, L=Hai Bà Trưng, CN= CÔNG TY CỔ PHẦN DƯỢC PHẨM TRUNG ƯƠNG 2, OID.0.9.2342.19200300.100.1.1= MST:0100109113
Reason: I am the author of this document
Location:
Date: 2026.07.16 16:32:13+07'00'
Foxit PDF Reader Version: 2024.1.0

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

No.: 213 / CV-DPTƯ2

Hanoi, Junly16, 2026

Re.: Explanation of a difference of more than 10% in operating profit in the second quarter of 2026 financial statements compared to the same period of previous year

To:
- **The State Securities Commission**
- **The Hanoi Stock Exchange**

Central Pharmaceutical Joint Stock Company NO2 (Stock symbol: **DP2**) would like to express our sincere greetings and thanks for your attention to our Company during the past time.

Complying with the Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance on guiding the disclosure of information on securities market:

As presented in the second quarter of 2026 financial statements dated Junly16, 2026 of Central Pharmaceutical Joint Stock Company NO2, the after-tax profit for this period of current year is: - VND 2,260,780,374, compared to the same period of previous year: VND 456,027,612.

DP2 hereby explains the operating profit as follows:

- In the second quarter of 2026, although the Company made its efforts to save the costs and reduce a cost of goods manufactured, the increase in foreign exchange rate led to higher raw material prices which caused the difficulties, challenges in production and business activities of the Company.
- In the second quarter of 2026, the pharmaceutical market faced many difficulties, challenges; so sales revenue decreased compared to the same period of previous year, and the profit decreased as a result.

DP2 kindly hopes for your consideration and assistance.
Sincerely thank!

Recipients:
- As mentioned above;
- Recorded; Archive, Finance and Accounting

CHIEF EXECUTIVE OFFICER



Pharmacist. Le Tien Dung